Skip to content
Screener

Exelixis EXEL Gross Profit

Gross Profit at other companies

Eli Lilly logo
Eli LillyLLY
$19.71B+50.3%
Pfizer logo
PfizerPFE
$10.94B+0.6%
Kura Oncology logo
Kura OncologyKURA
$18M
Opko Health logo
Opko HealthOPK
$80.02M+62.0%
Incyte logo
IncyteINCY
$1.57B+38.0%
CTO
Citius Oncology, Inc.CTOR
$1.34M

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Calculated from Exelixis’s reported figures.

The source filing: Exelixis’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098

FAQ

What is Exelixis's gross profit?
Exelixis (EXEL) reported gross profit of $608.03M in Q2 2026.
How has Exelixis's gross profit changed year-over-year?
Exelixis's gross profit increased by 10.8% year-over-year, from $548.79M to $608.03M.
What is the long-term trend for Exelixis's gross profit?
Over 4 years (2021 to 2025), Exelixis's gross profit has grown at a 12.8% compound annual growth rate (CAGR), from $1.38B to $2.24B.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.

Ask your AI about Exelixis's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude